728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

SQZ Biotech to Present at Investor Conferences in First Quarter 2018

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

WATERTOWN, Mass., Feb. 5, 2018 /PRNewswire/ — SQZ Biotech (SQZ), a preclinical stage biotechnology company developing cell therapies based on its proprietary CellSqueeze® technology, announced today that management will be presenting at three investor conferences in the first quarter of 2018.

BIO CEO and Investor Conference in New York, NY
February 12 – February 13, 2018
Presentation Time: February 12, 2018 at 10:30am

Cowen and Company Annual Healthcare Conference in Boston, MA
March 12 – March 14, 2018
Presentation Time: March 12, 2018 at 2:30pm

Oppenheimer Annual Healthcare Conference in New York, NY
March 20 – March 21, 2018
Presentation Time: March 21, 2018 at 8:35am

“We are thrilled to have the opportunity to present SQZ’s vision of developing a new generation of cell-based therapies,” remarked Armon Sharei, PhD, CEO at SQZ. “It is an honor to be selected as a private company and we look forward to discussing our potential to implement previously inaccessible therapies across multiple disease areas.”

About SQZ Biotech
SQZ Biotechnologies is a Massachusetts-based, privately held company developing cellular therapies for multiple indications using the proprietary CellSqueeze® technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies to address a wide range of clinical challenges. For more information please visit www.sqzbiotech.com.

SQZ Contact:
Rebecca Cohen
Manager, Corporate Relations & Administration
rebecca.cohen@sqzbiotech.com 
617-758-8672 ext. 728

SQZ Media Contact:
Justin Jackson
Burns McClellan 
212-213-0006, ext. 327 
jjackson@burnsmc.com

View original content:http://www.prnewswire.com/news-releases/sqz-biotech-to-present-at-investor-conferences-in-first-quarter-2018-300593144.html

SOURCE SQZ Biotechnologies

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *